On the Road to ROME: Defining Tissue–Liquid Concordance in Precision Oncology

A growing body of evidence has established liquid biopsy as a promising, noninvasive platform for genomic profiling. In this commentary, we build on findings from the multicenter, randomized phase II ROME trial and interrogate the challenges and opportunities of tissue-liquid profiling concordance in improving personalized cancer treatment and survival outcomes. See related article by Botticelli et al., p. 45.